Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

350 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An Early Warning Risk Prediction Tool (RECAP-V1) for Patients Diagnosed With COVID-19: Protocol for a Statistical Analysis Plan.
Fiorentino F, Prociuk D, Espinosa Gonzalez AB, Neves AL, Husain L, Ramtale SC, Mi E, Mi E, Macartney J, Anand SN, Sherlock J, Saravanakumar K, Mayer E, de Lusignan S, Greenhalgh T, Delaney BC. Fiorentino F, et al. JMIR Res Protoc. 2021 Oct 5;10(10):e30083. doi: 10.2196/30083. JMIR Res Protoc. 2021. PMID: 34468322 Free PMC article.
Predicting Risk of Hospital Admission in Patients With Suspected COVID-19 in a Community Setting: Protocol for Development and Validation of a Multivariate Risk Prediction Tool.
Espinosa-Gonzalez AB, Neves AL, Fiorentino F, Prociuk D, Husain L, Ramtale SC, Mi E, Mi E, Macartney J, Anand SN, Sherlock J, Saravanakumar K, Mayer E, de Lusignan S, Greenhalgh T, Delaney BC. Espinosa-Gonzalez AB, et al. Among authors: fiorentino f. JMIR Res Protoc. 2021 May 25;10(5):e29072. doi: 10.2196/29072. JMIR Res Protoc. 2021. PMID: 33939619 Free PMC article.
Remote COVID-19 Assessment in Primary Care (RECAP) risk prediction tool: derivation and real-world validation studies.
Espinosa-Gonzalez A, Prociuk D, Fiorentino F, Ramtale C, Mi E, Mi E, Glampson B, Neves AL, Okusi C, Husain L, Macartney J, Brown M, Browne B, Warren C, Chowla R, Heaversedge J, Greenhalgh T, de Lusignan S, Mayer E, Delaney BC. Espinosa-Gonzalez A, et al. Among authors: fiorentino f. Lancet Digit Health. 2022 Sep;4(9):e646-e656. doi: 10.1016/S2589-7500(22)00123-6. Epub 2022 Jul 28. Lancet Digit Health. 2022. PMID: 35909058 Free PMC article.
Statistical analysis plan for the Dual mTorc Inhibition in advanCed/recurrent Epithelial ovarian, fallopian tube or primary peritoneal cancer (of clear cell, endometrioid and high-grade serous type, and carcinosarcoma) trial (DICE).
de la Rosa CN, Krell J, Day E, Clarke A, Reddi M, Webber L, Fiorentino F. de la Rosa CN, et al. Among authors: fiorentino f. Trials. 2022 Jan 5;23(1):13. doi: 10.1186/s13063-021-05669-9. Trials. 2022. PMID: 34986897 Free PMC article. Clinical Trial.
Feasibility of Comparative Health Research Outcome of Novel Surgery in prostate cancer (IP4-CHRONOS): statistical analysis plan for the randomised feasibility phase of the CHRONOS study.
Day E, Prevost AT, Sydes MR, Reddy D, Shah TT, Winkler M, Dudderidge T, Staffurth J, McCracken S, Khoo V, Jadav P, Klimowska-Nassar N, Sasikaran T, Ahmed HU, Fiorentino F. Day E, et al. Among authors: fiorentino f. Trials. 2021 Aug 18;22(1):547. doi: 10.1186/s13063-021-05509-w. Trials. 2021. PMID: 34407860 Free PMC article. Clinical Trial.
IL-1 Signal Inhibition In Alcoholic Hepatitis (ISAIAH): a study protocol for a multicentre, randomised, placebo-controlled trial to explore the potential benefits of canakinumab in the treatment of alcoholic hepatitis.
Vergis N, Patel V, Bogdanowicz K, Czyzewska-Khan J, Fiorentino F, Day E, Cross M, Foster N, Lord E, Goldin R, Forrest E, Thursz M. Vergis N, et al. Among authors: fiorentino f. Trials. 2021 Nov 11;22(1):792. doi: 10.1186/s13063-021-05719-2. Trials. 2021. PMID: 34763711 Free PMC article.
350 results